Research Development on Cardiovascular Events Induced by Selective COX-2 Inhibitors

Abstract

Abstract: Reviewing the literatures about selective COX-2 inhibitors induce cardiovascular event among domestic and overseas. Analysing the toxicology, correlational research and serious adverse reaction events about selective COX-2 inhibitors induce cardiovascular event. Advising to pay close attention to patient cardiovascular situation when doctor using selective COX-2 inhibitors, and regularly monitor vital sign about cardiovascular situation.

Key words: NSAID, selective COX-2 inhibitors, cardiovascular event

WANG Nan, MAO Lu. Research Development on Cardiovascular Events Induced by Selective COX-2 Inhibitors[J]. Chinese Journal of Pharmacovigilance, 2012, 9(10): 625-627.

References

[1] Bombardier C, Laine L, Reicin A, et al. Comparison of Upper Gast-
rointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis[J].The New England journal of medicine. 2000,343(21):1520-1528.
[2] Bombardier C, Laine L, Burgos-Vargas R, et al.Response to expression of concern regarding VIGOR study[J].The New England journal of medicine. 2006,354 (11): 1196-1199.
[3] Merck & Co. Merck Announces Voluntary Worldwide Withdrawal of VIOXX, Retrieved 2004[R].
[4] Kate Hagan. Drug unfit for sale, says judge in compo case[EB/OL]. (2010-03-06 ) [2011-09-01]. http : //www.theage.com.au/national/drug-
unfit-for-sale-says-judge-in-copo-case-20100305-powh.html.
[5] Robert J. Campbell, MD and Kevin B. Acute Congestive Heart Failure Induced by Rofecoxib[J].The Journal of the American Board of Family Practice. 2004,17:131-135.
[6] Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis[J].Lancet. 2004, 364(9450):2021-9.
[7] Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA[J]. Lancet. 2004,364(9450):1995-6.
[8] Scott P A, Kingsley G H, Scott D L, et al. Non-steroidal anti-
inflammatory drugs and cardiac failure: meta-analyses of observ-
9 ational studies and randomised controlled trials[J].Eur J Heart Fail. 2008 ,10(11):1102-7.
[9] Bottone F G Jr, Barry W T. Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002[J]. Curr Med Res Opin. 2009,25(6):1535-50.
[10] Fosb l EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals[J]. Circ Cardiovasc Qual Outcomes. 2010,3(4):
395-405.
[11] Whitstock M T, Pearce C M, Ridout S C, et al. Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process[J].BMC Public Health. 2011,11:361.
[12] Arehart E, Stitham J, Asselbergs F W, et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition[J]. Circ Res. 2008,102(8):986-93.
[13] Jeanne Lenzer. Pfizer criticised over delay in admitting drug's problems[J], BMJ. 2004, 329(7472):935.
[14] Parecoxib[EB/OL].(2011-08-30.)[2011-09-01].http://en.wikip-
edia.org/wiki/Parecoxib.
[15] Zhang J, Ding E L, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of rand-
omized trials[J]. JAMA. 2006,296(13):1619-32.
[16] Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis[J]. BMJ.2011,11:342-6.